Clinical and Vaccine Immunology, June 2006, p. 711-714, Vol. 13, No. 6
1071-412X/06/$08.00+0 doi:10.1128/CVI.00031-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
David M. Anderson,1,2
Roy A. Hall,3
Robert B. Tesh,4
Amelia P. Travassos DaRosa,4 and
Helle Bielefeldt-Ohmann2,
Department of Comparative Medicine, Box 357190,1 Washington National Primate Research Center, Box 357330, University of Washington School of Medicine, Seattle, Washington 98195-7330,2 School of Molecular and Microbial Science, University of Queensland, St. Lucia, Queensland 4078, Australia,3 University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 775554
Received 26 January 2006/ Returned for modification 6 March 2006/ Accepted 23 March 2006
|
|
|---|
|
|
|---|
West Nile virus emerged in Louisiana during the spring of 2002, with endemic establishment and year-round regional virus activity reported during the winter months of 2003 to 2004 (12, 23). WNV and St. Louis encephalitis virus (SLEV) share a close phylogenetic relationship and elicit cross-reactive antibodies (5). Both viruses are maintained in similar transmission cycles with mosquito vectors (mainly Culex spp.), avian reservoirs, and amplification hosts. St. Louis encephalitis virus has been endemically established in the southern United States for many decades. Just prior to the emergence of WNV in Louisiana, a regional outbreak of SLEV took place (fall of 2001); SLEV and WNV now cocirculate within the region. Serological distinction between flaviviruses is hampered by the extensive homologies of viral structural proteins. West Nile virus infection exhibits low pathogenicity compared to many other members of the flavivirus family while producing broad-spectrum immunity (14). Sequential infections with one or more flaviviruses elicit strong cross-reactive anamnestic responses, which may confer immunity (22).
The Washington National Primate Research Center (WaNPRC) and the Tulane National Primate Research Center (TNPRC) house animals in the same outdoor breeding cohorts. The WNV seroprevalence in TNPRC animals was shown to be greater than 30% (18). We therefore aimed to assess the WNV exposure level among WaNPRC animals through serologic techniques (enzyme-linked immunosorbent assay [ELISA], immunofluorescence assays [IFAs], PRNT, and HAI). Since repeated exposures, persistent antibody response, and exposure to cocirculating flaviviruses can complicate the interpretation of serologic results, we also aimed to establish methods to discern between WNV and SLEV infections.
Of the cross-reactive viral structural proteins, the envelope (E) protein is the most immunogenic (25). The E protein is highly conserved among flaviviruses and elicits an antibody response with relatively low specificity. Cross-reactivity is confounding to assays that depend to a great extent on antibodies to the E protein, for example, HAI. This may be overcome, at least partially, by employing assays based on nonstructural (NS) proteins, which elicit more virus-specific immune responses.
A colony serosurvey was performed using a WNV epitope-blocking ELISA validated in multiple avian and mammalian species including the pig-tailed macaque (Macaca nemestrina) (3, 4, 8). ELISAs were performed using monoclonal antibody 3.112G (Chemicon International, Inc., Temecula, CA), which is specific for the NS1 protein of Kunjin virus, a subtype of WNV (7, 20). Immunoassays were performed with banked (70°C and 20°C) plasma samples collected from 1999 to 2005 for viral screening from approximately 700 WaNPRC pig-tailed macaques housed at the TNPRC in Covington, LA. Negative serum samples were obtained from WaNPRC animals born and housed indoors in Seattle, Washington. Western blot analysis was performed using infected Vero cell lysates (ChimeraVax SLEV and WNV; Acambis Int., Cambridge, MA) as previously described (2). Immunofluorescence assays (PanBio, Inc., Columbia, MD) were performed according to the manufacturer's specifications. Viral screening was performed under a general husbandry protocol approved by the University of Washington Institutional Animal Care and Use Committee. Both the WaNPRC and the TNPRC are AAALAC-accredited facilities. Hemagglutination inhibition assays were performed at the University of Texas Medical Branch using a previously published protocol (6). Previously obtained PRNT (Arthropod-Borne Infectious Disease Laboratory, Colorado State University) and HAI (University of Texas Medical Branch) data were used for correlation analysis (8).
Plasma samples collected at 6-month intervals from 1999 to 2005 were tested by ELISA. Samples from 2002 and 2003 were tested by HAI. No WNV-specific antibodies were detected in samples from 1999, 2000, or 2001. WNV antibodies were demonstrated in colony animals from 2002 to 2005.
The distribution of seroconversion and maintained titers among seropositive animals is summarized in Fig. 1. Seroconversion rates are a close approximation, as a small number of animals leave and enter the WaNPRC colony each year (7% average animal turnover from 2002 to 2004). Additionally, a small percentage of samples received were unsuitable for testing (0.5% in 2002, 1.1% in 2003, and 0.6% in 2004).
![]() View larger version (23K): [in a new window] |
FIG. 1. Distribution of seroconversion and maintained titers among seropositive animals surveyed from 2002 to 2005. The black bars represent the percentage of seroconversions; the dashed bars represent the percentage of maintained titers. In 2002, 40 previously naive animals developed WNV titers. In 2003, 69 animals were seropositive for WNV: 50 animals (72%) seroconverted, and 19 (28%) maintained ELISA titers from 2002. In 2004, 60 animals were positive for WNV: 25 animals (42%) seroconverted, and 35 (58%) maintained antibody titers (2002 or 2003). In 2005, 11% of the animals tested demonstrated WNV seroconversion by ELISA.
|
![]() View larger version (25K): [in a new window] |
FIG.2. ELISA results from 10 representative WNV-seropositive animals illustrating four possible reasons for persistent titers. (A) Viral exposure prior to the fall of 2002 with a gradual decline in antibody titers over the following 36 months. (B) Viral exposure prior to the fall of 2002 and a second exposure in 2004, evidenced by a rise in ELISA titer. (C) Viral exposure prior to the fall of 2002 and a second exposure in 2005, evidenced by a rise in ELISA titer. (D) Initial viral exposure during the winter of 2002 to 2003 with multiple subsequent exposures in 2003 and 2005.
|
![]() View larger version (99K): [in a new window] |
FIG. 3. Western blot illustrating multiple exposures to flavivirus. Four separate columns of WNV Vero cell lysates (reducing gel) reacted with four serum samples collected from one animal at 6- and 12-month intervals. Two distinct flaviviral protein bands are present on Western blots: NS5 protein (90 to 100 kDa) and a merging band of the E protein (50 kDa) and the NS1 protein (45 kDa). The E protein elicits the strongest antibody response. No reaction was seen on blots of noninfected Vero cells (not shown). The first column shows Precision Plus Protein Standards (Bio-Rad) run on a 10% Tris-HCl gel. Column 2 (t = 0) represents flavivirus reactivity due to a primary exposure. Column 3 (t = 6 months) represents a recent, second flaviviral exposure. Column 4 (t = 18 months) demonstrates decreased signal strength, correlating with falling ELISA titers. Column 5 (t = 30 months) represents a third exposure to a flavivirus.
|
![]() View larger version (122K): [in a new window] |
FIG. 4. Two Western blots illustrating the distinction between WNV and SLEV infection. Each blot consists of two columns; in the left column, serum proteins are reacting to WNV-infected cell lysates (reducing gel), while in the right column, serum proteins are reacting to SLEV-infected Vero cell lysates (reducing gel). The first column shows Precision Plus Protein Standards (Bio-Rad) run on a 10% Tris-HCl gel. Blot 1, serum from an animal infected with SLEV. The E protein signal is much stronger in the SLEV (right) column than in the WNV (left) column. Blot 2, serum from an animal infected with WNV. The E protein signal is present in the WNV (left) column and absent in the SLEV (right) column.
|
|
View this table: [in a new window] |
TABLE 1. SLEV and WNV reactivitiesa
|
When developing flaviviral monitoring programs for macaques in zoos and primate centers with outdoor facilities, complications in data interpretation from persistent antibody titers must be considered. Persistent titers may be related to continued flaviviral environmental exposure and/or the presence of cocirculating flaviviruses. We have demonstrated that macaques can maintain WNV seropositivity by ELISA for more than 36 months with continual environmental exposure. Western blots demonstrated repeated flavivirus exposure and discerned between WNV and SLEV exposures.
We gratefully acknowledge David Clark for the recombinant NS1 antigen, Thomas Monath (Acambis International) and the Centers for Disease Control (Fort Collins, CO) for West Nile virus and St. Louis encephalitis virus vaccine strains, the advice of Martine Jozan (California Vector Disease Control), and the assistance of the TNPRC and core staff at the WaNPRC.
Present address: SNBL USA, Ltd., 6605 Merrill Creek Parkway, Everett, WA 98203. ![]()
Present address: Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523-1619. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»